Annual report pursuant to Section 13 and 15(d)

DESCRIPTION OF BUSINESS (Details Narrative)

v3.22.1
DESCRIPTION OF BUSINESS (Details Narrative)
12 Months Ended
Jul. 17, 2019
Dec. 31, 2021
US [Member]    
Description Of Business [Line Items]    
Orphan drug designation provides market exclusivity period after marketing approval   7 years
EU [Member]    
Description Of Business [Line Items]    
Orphan drug designation provides market exclusivity period after marketing approval   10 years
Emmaus Life Sciences, Inc. [Member]    
Description Of Business [Line Items]    
Reverse split, conversion ratio 0.167  
Reverse split 1-for-6